Genentech doubles down on ADC-resistance via $1B DualityBio pact
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"Genentech doubles down on ADC-resistance via $1B DualityBio pact" is generating significant coverage in the Business category, with 5 articles from 5 distinct sources tracked by PULSE so far.
Outlets currently covering the story include PharmExec.com, finance.biggo.com, TradingView and Endpoints News. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 76d ago.
Quick answers
Why is "Genentech doubles down on ADC-resistance via $1B DualityBio pact" trending?
Because 5 independent news sources published 5 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (5)
- M&A Roundup: DualityBio & Genentech Enter Partnership to Develop Next Generation ADC’s, Teva Bids to Acquire Igalmi from BioXcel PharmExec.com · 78d ago
- Duality Biologics Partners with Roche's Genentech to Develop Next-Generation ADCs, Total Milestones Exceed $1 Billion finance.biggo.com · 78d ago
- Duality Biotherapeutics Says Global Research And Development Collaboration And License Agreement With Genentech TradingView · 78d ago
- Roche bets $1B+ on DualityBio's ADC tech to tackle payload resistance Endpoints News · 78d ago
- Genentech doubles down on ADC-resistance via $1B DualityBio pact Fierce Biotech · 78d ago
Topics
Related trends
Genentech pays Alector $100M for preclinical Parkinson’s prospect
Genentech has entered a global license agreement with Alector for a preclinical brain-penetrant enzyme replacement therapy targeting Parkinson's disease.
BioNTech-Genentech cancer vax records more deaths than control in scrapped ph. 2 test
BioNTech and Genentech have terminated a phase 2 mRNA colorectal cancer vaccine trial after safety reviews revealed more deaths than in the control group.
S.F. Genentech employee identified as first local victim of new opioid sold in smoke shops
Health officials in California have issued a warning after a Genentech employee became the first local victim of a new opioid sold in smoke shops.
Roche builds blockbuster BTK case for fenebrutinib in multiple sclerosis as FDA decision approaches
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Roche pens $2.5B pact for Hanmi’s clinical-stage obesity drug targeting less-explored mechanism
7 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.